SLC5A2 and type 2 diabetes mellitus: Within recent years, attention to heart failure (HF) care in patients with type 2 diabetes (T2D) has increased markedly after results from three randomized clinical trials (RCT) evaluating the effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors [1–3].